CAJ | 학술논문

目的：探讨冠心病应用成纤维细胞生产长因子治疗现状。方法本次选取80例冠心病患者，均为我院2013年5月～2014年5月收治，随机分组，就常规治疗（对照组，n=40）与联用成纤维细胞生长因子治疗（观察组，n=40）效果展开对比。结果观察组选取病例总有效率为97.5%，明显高于对照组80.0%（P＜0.05）。两组心功能CRP、LVPW、LVESD、LVEDD治疗前无明显差异（P＞0.05），疗后均改善，但观察组改善幅度明显优于对照组（P＜0.05）。结论冠心病采用成纤维细胞生长因子治疗，可显著提高预后，改善心功能，为临床治疗开辟了新的途径，使患者生存质量得到明显改善，对保障生命安全具有非常重要的意义。
목적：탐토관심병응용성섬유세포생산장인자치료현상。방법본차선취80례관심병환자，균위아원2013년5월～2014년5월수치，수궤분조，취상규치료（대조조，n=40）여련용성섬유세포생장인자치료（관찰조，n=40）효과전개대비。결과관찰조선취병례총유효솔위97.5%，명현고우대조조80.0%（P＜0.05）。량조심공능CRP、LVPW、LVESD、LVEDD치료전무명현차이（P＞0.05），료후균개선，단관찰조개선폭도명현우우대조조（P＜0.05）。결론관심병채용성섬유세포생장인자치료，가현저제고예후，개선심공능，위림상치료개벽료신적도경，사환자생존질량득도명현개선，대보장생명안전구유비상중요적의의。
Objective To investigate the research status of fiber cell growth factor in the treatment of coronary heart disease. Methods 80 cases with coronary heart disease patients in our hospital from May 2013 to May 2014 were selected, random allocation, the effect with usual care (control group,n=40) and in combination with fibroblast growth factor treatment (observation group,n=40) were compared.ResultsThe total effective rate of selected patients was 97.5%, significantly higher than 80.0% (P<0.05). Two heart function CRP, LVPW, LVESD, LVEDD treatment had no significant difference (P>0.05) before, were improved after treatment, but the magnitude of the improvement in the observation group was better than that in the control group (P<0.05).ConclusionCoronary heart disease using fibroblast growth factor therapy, can significantly improve the prognosis, improve heart function, for the clinical treatment has opened up new ways to make significant improvement in the quality of life of patients, to ensure the safety of very important significance.